Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib and R-CHOP for DLBCL
NCT02073097Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2015
- Primary completion
- Jul 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Case Comprehensive Cancer Center. Started Jan 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02073097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073097.